| Market Cap | ₹61,152.91 CrLarge Cap |
|---|---|
| Revenue TTM | ₹16,982.51 CrAnnual Operating |
| Piotroski Score | 8Strong Financials |
| RSI | 49.78Neutral Zone |
Key highlights
- Initiation of multi-country Phase 3 trial for Trastuzumab rezetecan in platinum-resistant ovarian cancer
- India becomes the first licensed market to receive DCGI approval for patient enrollment
- Study aligned with Jiangsu Hengrui Pharma parent Phase 3 trial currently ongoing in China
- Trastuzumab rezetecan is a first-in-class HER2-targeted antibody-drug conjugate (ADC)
- Glenmark holds exclusive rights for the asset across multiple global markets excluding China, USA, and Europe
The Product — What It Is
Trastuzumab rezetecan (SHR-A1811) is a HER2-targeted first-in-class antibody-drug conjugate (ADC) designed to treat HER2-expressing platinum-resistant ovarian cancer (PROC). This therapy combines the specificity of a monoclonal antibody with the potency of a cytotoxic drug to target cancer cells directly. Already conditionally approved in China for non-small cell lung cancer (NSCLC) and second-line breast cancer, the drug is now being evaluated for advanced gynecologic malignancies.
The Phase 3 trial is a randomized, controlled, multi-centre study that will assess efficacy, safety, and pharmacokinetics in diverse patient populations where existing treatment options remain limited.
Strategic Fit
The advancement of this trial aligns with Glenmark’s strategy to build a differentiated oncology pipeline for global markets. In September 2025, Glenmark entered an exclusive license agreement with Jiangsu Hengrui Pharmaceuticals to develop and commercialize the asset across multiple regions. This collaboration excludes major markets like the USA and Europe but covers significant territories including India, parts of Asia, and the CIS.
This move strengthens Glenmark’s presence in the high-growth oncology segment, leveraging externally developed innovation to address critical unmet medical needs in patients with difficult-to-treat solid tumors.
Industry Context
Ovarian cancer remains a significant global health challenge, ranking as the eighth most common cancer among women. India specifically carries a heavy burden of cases and deaths, with many patients developing resistance to standard platinum-based therapies. The industry shift toward Antibody-Drug Conjugates (ADCs) reflects a growing demand for targeted therapies that offer better precision than traditional chemotherapy.
Trastuzumab rezetecan has received Breakthrough Therapy Designation for nine indications in China, underscoring the therapeutic potential of this drug class in treating various HER2-overexpressing tumors, including gastric and colorectal cancers.
Business Overview
Glenmark Pharmaceuticals is a research-led global pharmaceutical company operating 11 manufacturing facilities across four continents and six R&D centers. The company maintains a commercial footprint in over 80 countries, focusing on core therapeutic areas including respiratory, dermatology, and oncology. Recognized as a top 100 biopharmaceutical company globally by sales, Glenmark combines its generic portfolio with innovative drug development to ensure broader patient access to high-quality medicines.
The company reported a consolidated annual operating revenue of ₹16,982.51 crore for the trailing twelve months, supported by a strong domestic and international presence.
Clinical Progress Quote
Advancing this pivotal Phase 3 trial marks an important step in Glenmark’s journey to build a differentiated oncology pipeline for global markets.
| Share price | ₹2167 |
|---|---|
| Market capitalisation | ₹61,152.91 Cr |
| Revenue (annual) | ₹16,982.51 Cr |
| Net profit (annual) | ₹1,361.85 Cr |
| Revenue (latest quarter) | ₹3,770.59 Cr-3.33% vs previous quarter |
| Net profit (latest quarter) | ₹301.41 Cr-25.25% vs previous quarter |
| P/E (TTM) | 44.9×Sector 41.85× |
| Promoter holding | 46.65%0.00% QoQ |
| FII holding | 20.35%Current quarter |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
Exchange filing by Glenmark Pharmaceuticals announcing the advancement of Phase 3 clinical trials for Trastuzumab rezetecan. Market figures from a third-party data provider.
